Sai Life Sciences Ltd 07 Nov 2025 12:00 AM
Sai Life Sciences consolidated net profit rises 101.98% in the September 2025 quarter,
Net profit of Sai Life Sciences rose 101.98% to Rs 83.84 crore in the quarter ended September 2025 as against Rs 41.51 crore during the previous quarter ended September 2024. Sales rose 35.88% to Rs 537.47 crore in the quarter ended September 2025 as against Rs 395.56 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales537.47395.56 36 OPM %27.1325.84 - PBDT151.8091.24 66 PBT112.0555.32 103 NP83.8441.51 102 Powered by Capital Market - Live News
Sai Life Sciences Ltd 25 Oct 2025 12:00 AM
Sai Life Sciences to conduct board meeting,
Sai Life Sciences will hold a meeting of the Board of Directors of the Company on 6 November 2025.Powered by Capital Market - Live News
Sai Life Sciences Ltd 08 Oct 2025 12:00 AM
Sai Life Sciences launches integrated CMC services,
Sai Life Sciences, Agility Life Sciences, and Centrix Pharma Solutions today announced the launch of an Integrated CMC Partnership designed to provide innovator biopharma companies with end-to-end Chemistry, Manufacturing and Controls (CMC) services. The collaboration combines the extensive CMC expertise of Sai Life Sciences in API development, Agility Life Sciences in formulation development, and Centrix Pharma Solutions in drug product development and clinical manufacturing. Through this partnership, customers will have access to integrated drug substance and drug product development, helping them move efficiently from preclinical studies to first-in-human (FIH) clinical trials and beyond. Powered by Capital Market - Live News
Sai Life Sciences Ltd 19 Sep 2025 12:00 AM
Sai Life Sciences allots 1.50 lakh equity shares under ESOP,
Sai Life Sciences has allotted 1,50,500 equity shares under ESOP on 03 September 2025. Powered by Capital Market - Live News
Sai Life Sciences Ltd 28 Aug 2025 12:00 AM
Sai Life Sciences commissions phase II of its production block in Bidar (Unit IV),
 Sai Life Sciences announced the completion of Phase II of its new Production Block (PB-11) at the company`s flagship API manufacturing facility in Bidar, India (Unit IV). The Phase I of PB-11, with a capacity of 110 KL, was inaugurated in December 2024. With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL, making it the single largest reactor volume block at the Bidar site. This expansion has taken the company`s total installed reactor capacity at the Bidar facility to ~700 KL.Powered by Capital Market - Live News
Subscribe for our
newsletter
Open Account Now